Nasdaq Combined Compos (COMPX.US)

Close: 12 199.00 (-7.11), Nov 30, 2020
Positive

Medium risk

Automatic technical analysis. Medium term, Nov 30, 2020

Nasdaq Combined Composite Index shows strong development within a rising trend channel in the medium long term. This signals increasing optimism among investors and indicates continued rise. The index has broken up through the resistance at points 12000. This predicts a further rise. In case of negative reactions, there will now be support at points 12000. The index is assessed as technically positive for the medium long term.

Recommendation one to six months: Positive (Score: 87)

Period  
Vol.bal. Volatility Liquidity +/- %
1 day-1.25%0.00-0.06%
5 days0.003.81%0.00+2.90%
22 days0.0010.47%0.00+10.85%
66 days0.0022.89%0.00+4.58%

More analyses of Nasdaq Combined Composite Index

chart Nasdaq Combined Composite Index (COMPX) Candlesticks 22 Days
Candlesticks
chart Nasdaq Combined Composite Index (COMPX) Short term
Short term: Positive
chart Nasdaq Combined Composite Index (COMPX) Medium term
Medium term: Positive
chart Nasdaq Combined Composite Index (COMPX) Long term
Long term: Positive
 


Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer. The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.


Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer. The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.

Titlex

OK
Free Trial Now